Skip to main content
Top
Published in: Current Atherosclerosis Reports 1/2015

01-01-2015 | Statin Drugs (BS Wiggins, Section Editor)

When Compliance Is an Issue—How to Enhance Statin Adherence and Address Adverse Effects

Author: Kim Birtcher

Published in: Current Atherosclerosis Reports | Issue 1/2015

Login to get access

Abstract

Cardiovascular disease is prevalent and costly. Interventions and therapies that reduce morbidity and mortality associated with cardiovascular disease could have an enormous impact on clinical and economic outcomes. Statins reduce atherosclerotic cardiovascular disease-related morbidity and mortality; however, adherence to statins is less than optimal. It is important for clinicians as well as health plan managers to be aware of the patient- and insurance plan-specific factors that have been shown to influence adherence. Perceived statin-related side effects may also decrease adherence. Statin-related myalgia may be difficult to distinguish from myalgia caused by other conditions, and statin therapy may be discontinued unnecessarily in patients who would otherwise benefit. It is imperative that clinicians work closely with patients to improve adherence to statin therapy and be knowledgable in managing potential statin-related side effects.
Literature
1.
go back to reference Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292.PubMedCrossRef Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292.PubMedCrossRef
2.
go back to reference Cholesterol Trialists Collaboration, Baigent C, Blackwell L, Emberson J, et al. Lancet. 2010;376:1670–81.PubMedCrossRef Cholesterol Trialists Collaboration, Baigent C, Blackwell L, Emberson J, et al. Lancet. 2010;376:1670–81.PubMedCrossRef
3.
go back to reference Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014; 63(25_PA) doi: 10.1016/j.jacc.2013.11.002. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014; 63(25_PA) doi: 10.​1016/​j.​jacc.​2013.​11.​002.
4.
go back to reference Pencina MJ, Navar-Boggan AM, D’Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422–31.PubMedCrossRef Pencina MJ, Navar-Boggan AM, D’Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422–31.PubMedCrossRef
5.
go back to reference Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.PubMedCrossRef Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.PubMedCrossRef
6.
go back to reference Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.PubMedCrossRef Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.PubMedCrossRef
7.
go back to reference Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638–45.PubMedCentralPubMedCrossRef Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638–45.PubMedCentralPubMedCrossRef
8.
go back to reference Vinker S, Shani M, Baevsky T, et al. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14(6):388–92.PubMed Vinker S, Shani M, Baevsky T, et al. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14(6):388–92.PubMed
9.
go back to reference Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a U.S. managed care study. Curr Med Res Opin. 2008;24(7):1987–2000.PubMedCrossRef Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a U.S. managed care study. Curr Med Res Opin. 2008;24(7):1987–2000.PubMedCrossRef
10.
go back to reference Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8.PubMedCrossRef Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8.PubMedCrossRef
11.
go back to reference Mann DM, Woodward M, Muntner P, et al. Predictors of non-adherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44:1410–21.PubMedCentralPubMedCrossRef Mann DM, Woodward M, Muntner P, et al. Predictors of non-adherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44:1410–21.PubMedCentralPubMedCrossRef
12.
go back to reference Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574–80.PubMedCrossRef Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574–80.PubMedCrossRef
13.
go back to reference Cohen JD, Brinton EA, Ito MK, et al. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–15.PubMedCrossRef Cohen JD, Brinton EA, Ito MK, et al. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–15.PubMedCrossRef
14.
go back to reference Kazerooni R, Watanabe JH, Bounthavong M. Association between statin adherence and cholesterol level reduction from baseline in a veteran population. Pharmacotherapy. 2013;33(10):1044–52.PubMed Kazerooni R, Watanabe JH, Bounthavong M. Association between statin adherence and cholesterol level reduction from baseline in a veteran population. Pharmacotherapy. 2013;33(10):1044–52.PubMed
15.
go back to reference Chi MD, Vansomphone SS, Liu IA, et al. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care. 2014;20(4):e105–12.PubMed Chi MD, Vansomphone SS, Liu IA, et al. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care. 2014;20(4):e105–12.PubMed
16.
go back to reference Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.PubMedCrossRef Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.PubMedCrossRef
17.
go back to reference Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013–24.PubMedCrossRef Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013–24.PubMedCrossRef
18.
go back to reference Zhao Y, Zabriski S, Bertram C. Associations between statin adherence level, health care costs, and utilization. J Manag Care Pharm. 2014;20(7):703–13.PubMed Zhao Y, Zabriski S, Bertram C. Associations between statin adherence level, health care costs, and utilization. J Manag Care Pharm. 2014;20(7):703–13.PubMed
19.
go back to reference Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Spec no.:SP11–19. Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Spec no.:SP11–19.
20.
go back to reference Aubert RE, Yao J, Xia F, et al. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459–66.PubMed Aubert RE, Yao J, Xia F, et al. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459–66.PubMed
21.
go back to reference Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63(6):698–708.PubMedCentralPubMedCrossRef Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63(6):698–708.PubMedCentralPubMedCrossRef
22.
go back to reference Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issue. Value Health. 2010;13(1):87–94.PubMedCrossRef Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issue. Value Health. 2010;13(1):87–94.PubMedCrossRef
23.•
go back to reference Pittman DG, Chen W, Zhao Y, Zabriski S, Bertram C. Associations between statin adherence level, health care costs, and utilization. J Manag Care Pharm. 2014;20(7):703–13. This study demonstrates the association between better statin adherence for a 1-year period with lower healthcare costs and fewer cardiovascular disease-related hospitalizations during the subsequent 18 months. Clinicians and health benefits managers should emphasize statin adherence in the first year. Pittman DG, Chen W, Zhao Y, Zabriski S, Bertram C. Associations between statin adherence level, health care costs, and utilization. J Manag Care Pharm. 2014;20(7):703–13. This study demonstrates the association between better statin adherence for a 1-year period with lower healthcare costs and fewer cardiovascular disease-related hospitalizations during the subsequent 18 months. Clinicians and health benefits managers should emphasize statin adherence in the first year.
24.••
go back to reference Slejko JF, Ho PM, Anderson HD, et al. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51–7. The authors demonstrated that statin adherence declines over a 3-year period even if the patient is adherent during the first year of therapy, and transition to adherence levels <80 % was associated with increased cardiovascular events. The second-year adherence level was a significant predictor of cardiovascular event hazard (p < 0.001). Clinicians and health benefits managers should emphasize statin adherence long-term. PubMed Slejko JF, Ho PM, Anderson HD, et al. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51–7. The authors demonstrated that statin adherence declines over a 3-year period even if the patient is adherent during the first year of therapy, and transition to adherence levels <80 % was associated with increased cardiovascular events. The second-year adherence level was a significant predictor of cardiovascular event hazard (p < 0.001). Clinicians and health benefits managers should emphasize statin adherence long-term. PubMed
25.
go back to reference Fischer MA, Stedman MR, Lii J, et al. Primary medication nonadherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–90.PubMedCentralPubMedCrossRef Fischer MA, Stedman MR, Lii J, et al. Primary medication nonadherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–90.PubMedCentralPubMedCrossRef
26.
go back to reference Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary nonadherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med. 2012;27(1):57–64.PubMedCentralPubMedCrossRef Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary nonadherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med. 2012;27(1):57–64.PubMedCentralPubMedCrossRef
27.
go back to reference Liberman JN, Hutchins DS, Popiel RG, et al. Determinants of primary nonadherence in asthma-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits. 2010;2(2):111–8. Liberman JN, Hutchins DS, Popiel RG, et al. Determinants of primary nonadherence in asthma-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits. 2010;2(2):111–8.
28.
go back to reference Cheetham TC, Niu F, Green K, et al. Primary nonadherence to statin medications in a managed care organization. J Manag Care Pharm. 2013;19(5):367–73.PubMed Cheetham TC, Niu F, Green K, et al. Primary nonadherence to statin medications in a managed care organization. J Manag Care Pharm. 2013;19(5):367–73.PubMed
29.•
go back to reference Zimolzak AJ, Spettell CM, Fernandes J, et al. Early detection of poor adherers to statins: applying individualized surveillance to pay for performance. PLoS ONE. 2013;8(11):e79611. Lower adherence (PDC <0.80) in the first 90 days of statin therapy was the strongest predictor for poor adherence at 1 year (OR 25.0, 95 % CI 23.7–26.5) in patients initiating statin therapy. Predictions could be made as early as 40 days after statin initiation for individuals who get 30-day supplies of medication and 100 days after statin initiation for individuals who get 90-day supplies of medication. Plan administrators and pharmacy benefits managers could use an individualized surveillance model similar to the one used in this study to detect early which beneficiaries will fall below the designated adherence threshold. PubMedCentralPubMedCrossRef Zimolzak AJ, Spettell CM, Fernandes J, et al. Early detection of poor adherers to statins: applying individualized surveillance to pay for performance. PLoS ONE. 2013;8(11):e79611. Lower adherence (PDC <0.80) in the first 90 days of statin therapy was the strongest predictor for poor adherence at 1 year (OR 25.0, 95 % CI 23.7–26.5) in patients initiating statin therapy. Predictions could be made as early as 40 days after statin initiation for individuals who get 30-day supplies of medication and 100 days after statin initiation for individuals who get 90-day supplies of medication. Plan administrators and pharmacy benefits managers could use an individualized surveillance model similar to the one used in this study to detect early which beneficiaries will fall below the designated adherence threshold. PubMedCentralPubMedCrossRef
30.
go back to reference Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15:291–8.PubMedCentralPubMedCrossRef Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15:291–8.PubMedCentralPubMedCrossRef
31.
go back to reference Romanelli RJ, Segal JB. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries. J Gen Intern Med. 2014;24. Romanelli RJ, Segal JB. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries. J Gen Intern Med. 2014;24.
32.
go back to reference Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.PubMedCrossRef Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.PubMedCrossRef
33.
go back to reference EaddyMT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012;37:45–55. EaddyMT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012;37:45–55.
34.
go back to reference Maciejewski ML, Farley JF, Parker J, et al. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002–8.CrossRef Maciejewski ML, Farley JF, Parker J, et al. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002–8.CrossRef
35.
go back to reference Thiebaud P, Patel BV, Nichol MB. The demand for statin: the effect of copay on utilization and compliance. Health Econ. 2008;17(1):83–97. 24. PubMedCrossRef Thiebaud P, Patel BV, Nichol MB. The demand for statin: the effect of copay on utilization and compliance. Health Econ. 2008;17(1):83–97. 24. PubMedCrossRef
36.
go back to reference Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748–57.PubMedCrossRef Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748–57.PubMedCrossRef
37.
go back to reference Chen S, Shah SN, Lee Y, et al. Moving branded statins to lowest copay tier improves patient adherence. J Manag Care Pharm. 2014;20(1):34–42.PubMed Chen S, Shah SN, Lee Y, et al. Moving branded statins to lowest copay tier improves patient adherence. J Manag Care Pharm. 2014;20(1):34–42.PubMed
38.•
go back to reference Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014;20(1):43–50. This study demonstrated better adherence with statins for new statin users who did not have a copayment for their statin versus patients who had a copayment for their statins. It will be important for insurance benefits managers to evaluate total healthcare costs of eliminating or reducing copayments for prescriptions medications. In the long-run, the plan may benefit from less expenditures and better clinical outcomes. PubMed Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014;20(1):43–50. This study demonstrated better adherence with statins for new statin users who did not have a copayment for their statin versus patients who had a copayment for their statins. It will be important for insurance benefits managers to evaluate total healthcare costs of eliminating or reducing copayments for prescriptions medications. In the long-run, the plan may benefit from less expenditures and better clinical outcomes. PubMed
39.••
go back to reference Choudhry NK, Avorn J, Glynn RJ, et al. Post-myocardial infarction free Rx event and economic evaluation (MI FREEE) trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97. This study demonstrated better adherence with statins and better clinical outcomes for new statin users who did not have a copayment for their statin versus patients who had a copayment for their statins. It will be important for insurance benefits managers to evaluate total healthcare costs of eliminating or reducing copayments for prescriptions medications. In the long-run, the plan may benefit from less expenditures and better clinical outcomes. PubMedCrossRef Choudhry NK, Avorn J, Glynn RJ, et al. Post-myocardial infarction free Rx event and economic evaluation (MI FREEE) trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97. This study demonstrated better adherence with statins and better clinical outcomes for new statin users who did not have a copayment for their statin versus patients who had a copayment for their statins. It will be important for insurance benefits managers to evaluate total healthcare costs of eliminating or reducing copayments for prescriptions medications. In the long-run, the plan may benefit from less expenditures and better clinical outcomes. PubMedCrossRef
41.
go back to reference Daugherty JB, Maciejewski ML, Farley JF. The impact of manufacturer coupon use in the statin market. Manag Care Pharm. 2013;19(9):765–72. Daugherty JB, Maciejewski ML, Farley JF. The impact of manufacturer coupon use in the statin market. Manag Care Pharm. 2013;19(9):765–72.
42.••
go back to reference Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. Ann Intern Med. 2013;158:526–34. Statin rechallenging is a viable option for some patients who report statin-related side effects. PubMedCentralPubMedCrossRef Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. Ann Intern Med. 2013;158:526–34. Statin rechallenging is a viable option for some patients who report statin-related side effects. PubMedCentralPubMedCrossRef
43.••
go back to reference Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603. Statin rechallenging is a viable option for some patients who report statin-related side effects. Patients on intermittent statin dosing achieved similar LDL-C reductions to patients on daily statin dosing. PubMedCentralPubMedCrossRef Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603. Statin rechallenging is a viable option for some patients who report statin-related side effects. Patients on intermittent statin dosing achieved similar LDL-C reductions to patients on daily statin dosing. PubMedCentralPubMedCrossRef
44.•
go back to reference Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013;47:398–404. The authors noted that at least 70 % of patients with prior statin-related side effects were able to tolerate intermittent statin dosing, ranging from every-other-day to once-weekly dosing, without a recurrence of previous statin-related adverse effects. PubMedCrossRef Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013;47:398–404. The authors noted that at least 70 % of patients with prior statin-related side effects were able to tolerate intermittent statin dosing, ranging from every-other-day to once-weekly dosing, without a recurrence of previous statin-related adverse effects. PubMedCrossRef
45.••
go back to reference Joy TR, Monjed A, Zou GY. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301–10. Statin rechallenging is a viable option for some patients who report statin-related side effects. Though the investigators and patients in this study used matching statin and placebo doses, the other methodology used to discern the difference in side-effects to statin and placebo could be used in other clinical settings. PubMedCrossRef Joy TR, Monjed A, Zou GY. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301–10. Statin rechallenging is a viable option for some patients who report statin-related side effects. Though the investigators and patients in this study used matching statin and placebo doses, the other methodology used to discern the difference in side-effects to statin and placebo could be used in other clinical settings. PubMedCrossRef
46.
go back to reference Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMedCrossRef Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMedCrossRef
47.
go back to reference Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71.PubMedCentralPubMedCrossRef Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71.PubMedCentralPubMedCrossRef
48.••
go back to reference Dixon D, Nash D, Bolick J, et al. Patient adherence tool kit. https://www.lipid.org/practicetools/tools/adherence. Accessed 30 May 2014. The toolkit challenges clinicians to view adherence as a disease, which will require an understanding what represents adherence, how to “diagnose” it in patients, and what evidence-based interventions have been successful at improving patient adherence. Dixon D, Nash D, Bolick J, et al. Patient adherence tool kit. https://​www.​lipid.​org/​practicetools/​tools/​adherence. Accessed 30 May 2014. The toolkit challenges clinicians to view adherence as a disease, which will require an understanding what represents adherence, how to “diagnose” it in patients, and what evidence-based interventions have been successful at improving patient adherence.
Metadata
Title
When Compliance Is an Issue—How to Enhance Statin Adherence and Address Adverse Effects
Author
Kim Birtcher
Publication date
01-01-2015
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 1/2015
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-014-0471-8

Other articles of this Issue 1/2015

Current Atherosclerosis Reports 1/2015 Go to the issue

Statin Drugs (BS Wiggins, Section Editor)

What the Guidelines Do Not Say: Statin Non-benefit Groups

New Drugs Approved for Homozygous FH (SS Virani, Section Editor)

Recommendations for the Management of Patients with Familial Hypercholesterolemia

Statin Drugs (BS Wiggins, Section Editor)

Statins and Delirium: Is There a Role?

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.